Search
Close this search box.
Our Purpose:
We are focused on
delivering healthcare innovation
to improve the lives of patients with vascular disease.

Leadership

Board of Directors

Sumner Anderson

Member of the Board

Richard Mott

Executive Chairman of the Board

Matt Thompson, M.D.

President and Chief Executive Officer

Lucas Buchanan

Member of the Board

Andrew ElBardissi, M.D.

Member of the Board

Abraham Kometz, M.D.

Member of the Board

Bryan Sendrowski

Member of the Board

Art Taylor

Member of the Board

Scott Ward

Member of the Board

Member of the Board

Sumner Anderson

Sumner Anderson is a Partner on the Public Structured Finance group at Deerfield and joined the Firm in 2012 as a member of the Pharmaceuticals group, providing extensive research and analysis on individual companies operating in the healthcare industry. He transitioned to the Public Structured Finance Group in 2019. Prior to Deerfield, Mr. Anderson was a research analyst covering pharmaceuticals at Millennium Management. Before Millennium, he was a Managing Director in healthcare investment banking at Wells Fargo Securities and a pharmaceutical analyst in Global Equities at Citadel Investment Group. Mr. Anderson’s healthcare investment career has been split between investment banking and equity long short funds. He holds an A.B. in History and Economics from Harvard University, and an M.B.A. with an emphasis in Finance and Accounting from New York University.

Executive Chairman of the Board

Richard Mott

Rich joined Endologix as a member of the Board in June 2020. Upon our incorporation on October 1, 2020, Rich was appointed Executive Chairman of the Board. Rich is currently a principal in Walkabout Consulting LLC, a management consulting and private equity firm, which he founded in 2008. Rich served as President and Chief Executive Officer and Director of Kyphon Inc., a NASDAQ-listed global medical device company focused on minimally invasive spinal therapies, from 2002 through its acquisition by Medtronic, Inc. in late 2007. Prior to Kyphon, Rich held several executive positions at Wilson Greatbatch Technologies, Inc., most recently as Chief Operating Officer, as well as executive operating roles within the Bristol-Myers Squibb Company. Rich currently serves on the Board of Directors of several private companies, including Conventis Orthopedics, Sollis Therapeutics, Treace Medical Concepts, Relievant Med Systems, and Arsenal Medical. He is the previous recipient of the Ernst & Young Entrepreneur of the Year Award and the Frost & Sullivan Technology Leadership of the Year Award. Rich holds a BS in Ceramic Engineering from Alfred University and is a Graduate of Harvard University’s Advanced Management Program.

President and Chief Executive Officer

Matt Thompson, M.D.

Dr. Matt Thompson is the President and Chief Executive Officer (CEO) of Endologix LLC. Prior to his CEO appointment in November 2021, he served as the company’s Chief Medical Officer (CMO) from 2016, overseeing business development, medical affairs, regulatory, clinical, and R&D departments. Among his notable contributions as CMO was to lead the  acquisition and integration of PQ Bypass in April 2021.

Previously he was the Professor of Vascular Surgery at St George’s, University of London and Staff Surgeon in the Department of Vascular Surgery at the Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Ohio. Dr. Thompson trained at Cambridge, St Bartholomew’s Hospital, the University of Leicester and Adelaide. He studied corporate innovation at Stanford University, Graduate School of Business. His awards include a Hunterian Professorship, the Moynihan travelling fellowship and the gold medal for the intercollegiate examination. His named lectures include the Kinmonth Lecture (Vascular Society Great Britain and Ireland), the British Journal of Surgery Lecture (Vascular Society Great Britain and Ireland), and the Chee Song Memorial Lecture (British Society of Endovascular Therapy). He has published over 400 peer reviewed articles.

His clinical interests were in the treatment of aortic disease and endovascular surgery. His research interests include health service outcome research, clinical trials, and translational investigations into aortic disease. Dr. Thompson is the editor of the Oxford Textbook of Vascular Surgery and the Oxford Handbook of Vascular Surgery. He has been the clinical director for three London-wide service reconfigurations (cardiovascular disease, major trauma, and emergency services). He was Chair of the National Specialized Commissioning Clinical Reference Group for Vascular Services. He is a founder of the British Society for Endovascular Therapy, a past Council Member of the Vascular Society, was Chairman of the Vascular Society Annual Scientific Meeting and was awarded a Lifetime Achievement Award by the Vascular Society of Great Britain and Ireland in 2017.

Member of the Board

Lucas Buchanan

Lucas Buchanan leads manufacturing and operations, finance and accounting, IT, commercial operations and analytics, health economics and reimbursement, and corporate development efforts for Silk Road Medical. Prior to joining the company full time in 2012, Lucas was an investment professional with The Vertical Group, the founding investor in Silk Road, where he helped lead the company through early development and financing milestones while charting the company’s commercial strategy. Also while at The Vertical Group, Lucas led investments in Atheromed (acquired by Volcano Corporation) and Lutonix (acquired by CR Bard). Lucas has also held various leadership positions in marketing and corporate development/M&A at Impax Laboratories and Medtronic and began his career at Ernst & Young Corporate Finance LLC where he advised healthcare companies on financing and M&A transactions. Lucas holds a B.A. in Economics from Duke University and M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania.

Member of the Board

Andrew ElBardissi, M.D.

Andrew ElBardissi, M.D., is a Partner on the Medical Devices team at Deerfield and joined the Firm in 2017. Prior to Deerfield, Dr. ElBardissi was a Principal at Longitude Capital, where he focused on investments in medtech and biotechnology. Before that, he was an Associate in JPMorgan’s healthcare investment banking practice. Dr. ElBardissi received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. He has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has authored over 30 publications in leading peer-reviewed scientific journals and has presented his research at numerous medical and surgical conferences. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University.

Member of the Board

Abraham Kometz, M.D.

Avi Kometz, M.D., is a Partner on the Medical Devices group at Deerfield and joined the Firm in 2014. Prior to Deerfield, Dr. Kometz was a Partner at Ascent Biomedical Ventures, where he led investment efforts in biotechnology, pharmaceuticals, medical devices and healthcare information technology. Before Ascent, Dr. Kometz served as the head of corporate development at a specialty pharmaceutical company focused on pediatrics. He was also a member of the Healthcare Practice at McKinsey & Company in New York, where he worked on matters including strategy, valuation, organizational change and cost-reduction. Dr. Kometz received his medical doctorate from the University of the Witwatersrand Medical School, South Africa. He began his career as a clinician in South Africa and went on to found and build a group of clinics.

Member of the Board

Bryan Sendrowski

Bryan Sendrowski is a Partner on the External Operations team at Deerfield and joined the Firm in 2012. He is responsible for the day to day oversight and management of certain investments in Deerfield’s Private Design and Healthcare Innovations Funds. Prior to joining Deerfield, Mr. Sendrowski was Chief Financial Officer of New American Therapeutics, a specialty pharmaceutical company that was funded and facilitated by Deerfield’s Private Design Funds. Before New American Therapeutics, he was Chief Financial Officer at Akrimax Pharmaceuticals and Vice President and Controller of Reliant Pharmaceuticals. He also previously served as a Senior Manager in the financial statement audit practice of KPMG, LLP with responsibility for the management of public and private company audits. Mr. Sendrowski received his B.A. from Pace University and is licensed (inactive) as a Certified Public Accountant in the state of New Jersey.

Member of the Board

Art Taylor

Art Taylor has over 30 years of experience in operational and financial executive leadership within the medical device, pharmaceutical, and high-tech industries. Mr. Taylor’s expertise extends to both publicly held companies and private, venture capital-backed firms. His sector experience is diverse, encompassing spine, electrophysiology, ophthalmology, hearing healthcare, and neurology. Mr. Taylor served as a member of the Board of Directors for several medical device firms that were subsequently acquired and is currently a Board member for three early stage companies, and Providence Medical Technology, a commercial stage company.

Member of the Board

Scott Ward

Scott Ward was most recently the CEO and Chairman of the Board of Cardiovascular Systems. Over the course of his career, he has served on over 15 public and private company Boards as well as numerous non-profit Boards, including Gillette Children’s where he is currently the Chairman of the Philanthropy Board. Mr. Ward has over 40 years of experience in the healthcare industry, including nearly 30 years at Medtronic, Inc. where he served in various leadership roles including the Senior Vice President and President of the CardioVascular, Neurological and Diabetes businesses. Mr. Ward is the Founder of Raymond Holdings, a firm with activities in venture capital, strategy and transactional advisory services for medical technology and life science companies.

President and Chief Executive Officer

Matt Thompson, M.D.

Dr. Matt Thompson is the President and Chief Executive Officer (CEO) of Endologix LLC. Prior to his CEO appointment in November 2021, he served as the company’s Chief Medical Officer (CMO) from 2016, overseeing business development, medical affairs, regulatory, clinical, and R&D departments. Among his notable contributions as CMO was to lead the  acquisition and integration of PQ Bypass in April 2021.

Previously he was the Professor of Vascular Surgery at St George’s, University of London and Staff Surgeon in the Department of Vascular Surgery at the Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Ohio. Dr. Thompson trained at Cambridge, St Bartholomew’s Hospital, the University of Leicester and Adelaide. He studied corporate innovation at Stanford University, Graduate School of Business. His awards include a Hunterian Professorship, the Moynihan travelling fellowship and the gold medal for the intercollegiate examination. His named lectures include the Kinmonth Lecture (Vascular Society Great Britain and Ireland), the British Journal of Surgery Lecture (Vascular Society Great Britain and Ireland), and the Chee Song Memorial Lecture (British Society of Endovascular Therapy). He has published over 400 peer reviewed articles.

His clinical interests were in the treatment of aortic disease and endovascular surgery. His research interests include health service outcome research, clinical trials, and translational investigations into aortic disease. Dr. Thompson is the editor of the Oxford Textbook of Vascular Surgery and the Oxford Handbook of Vascular Surgery. He has been the clinical director for three London-wide service reconfigurations (cardiovascular disease, major trauma, and emergency services). He was Chair of the National Specialized Commissioning Clinical Reference Group for Vascular Services. He is a founder of the British Society for Endovascular Therapy, a past Council Member of the Vascular Society, was Chairman of the Vascular Society Annual Scientific Meeting and was awarded a Lifetime Achievement Award by the Vascular Society of Great Britain and Ireland in 2017.

Chief Financial Officer

Cindy Pinto

Cindy Pinto was appointed as the Chief Financial Officer in March 2021 after serving as the Interim CFO and principal financial officer since June 2020. During her tenure, she has held various positions in the Finance Department, most recently she was the Vice President, Financial Planning and Analysis. Prior to that, Cindy served as the Company’s Senior Finance Director from February 2016 through September 2018 and as Finance Director from September 2014 through January 2016. Prior to joining Endologix, Cindy served as Finance Director at Covidien. She received a BS in Accounting from Villanova University and an MBA from New York University. During her free time Cindy enjoys hiking, traveling and spending time with her family.

Chief Commercial Officer

Mike Mathias

Mike joined Endologix as the Chief Commercial Officer in March 2024. Mike Mathias has spent his thirty-year career successfully leading commercial organizations in the cardiovascular space. Most recently, he played a seminal role as Vice President, Commercial Operations at LimFlow, Inc. which Inari Medical acquired. As the LimFlow, Inc., commercial leader, he led the development and execution of the LimFlow System’s U.S. commercial launch. Prior to joining LimFlow, Inc., he spent 20 years in various commercial leadership roles at Medtronic. He led Medtronic’s $1.2 billion Heart Valve Therapies U.S commercial operations, launching TAVR (Transcatheter Aortic Valve Replacement). Prior to leading the Heart Valve Therapies commercial organization, he held sales management roles across Medtronic’s cardiology, endovascular, cardiac surgery, peripheral, perfusion, and cardiac rhythm businesses, as well as a variety of sales roles in the cardiology franchise for Pfizer. He earned a B.S. in Arabic and French Studies at the U.S. Military Academy at West Point and holds a master’s degree in business administration from the University of Minnesota.

Chief Operating Officer

Beth Rothwell

Beth joined Endologix as the Chief Operating Officer in September 2022. She is currently a Managing Partner and the co-founder of Sequoia Ventures, a provider of investment capital and strategic leadership to growing middle-market businesses. In 2008 she co-founded VFD Technologies, Inc., a precision medical device and robotics manufacturing company, where she served on the board of directors and for thirteen years served as the President and Chief Commercial Officer for the four manufacturing entities. Acquired by Arch Global Precision in 2021, the company now operates as Arch Medical Solutions. Prior to VFD, Beth served as Vice President of Operations and Quality of Kyphon Inc., a NASDAQ-listed global medical device company focused on minimally invasive spinal therapies, from 2002 through its acquisition by Medtronic, Inc. in late 2007 and with Medtronic through 2008. Prior to Kyphon, Beth served as a Board of Director Member and Vice President for Intercon, Inc. a contract manufacturing firm specializing in fiber and electrical assemblies for a variety of markets. Ms. Rothwell holds a M.S. in Biomedical Engineering from Virginia Polytechnic Institute and a B.S. in Ceramic Engineering from Alfred University. She is also a graduate of the Harvard Business School’s Women in Leadership Program.

Vice President, Sales Americas

Christopher Leach

Chris was named VP of US Sales in November 2020 after being at Endologix for eight years. During his tenure he served key management roles, most recently, as a key leader in the business, serving as the Area Sales Director of the Eastern region. Chris has also served as our Director, Global Professional Education and was a Regional Sales Manager at TriVascular prior to the merger with Endologix in 2016. Before joining Endologix, Chris was at Abbott Vascular for twelve years in the peripheral vascular division as a Regional Manager. He has a degree in Biology from Xavier University in Cincinnati. During his free time, Chris spends as much time as possible with his wife and two kids, he is an avid guitarist and has been known to play on a stage or two.

Vice President, Engineering

Matt Poole

Matt has over 25 years of experience within the medical device industry, having roles within the R&D and Operations functions of global corporations and emerging technical companies. Prior to being appointed as the VP, Engineering at Endologix, he held various leadership positions within the Engineering department, most recently as the Senior Director of Manufacturing Engineering. Previous to Endologix, Matt held leadership positions of increasing responsibility over his 25 year career with Medtronic CardioVascular in Danvers, MA and with the Medtronic Coronary/Renal Denervation/Structural Heart divisions in Santa Rosa, CA. Matt’s diverse and extensive experience comes from executing as a functional, technical, and program leader across numerous internal and external development programs, along with cross business partnerships within the Peripheral and Cardiac Rhythm Management space.

Matt holds a BS in Industrial Engineering and an AS in Plastic Engineering Technology from the University of Massachusetts-Lowell and has attended MIT Sloan School of Management for Executive MBA studies. During his spare time, he enjoys ice hockey, golf, winemaking, and spending time with his family.

Vice President, Health Economics & Reimbursement

Chip Richter

Chip Richter joined Endologix as Vice President of Health Economics & Reimbursement in January 2023. He is a healthcare executive and leader with over two decades of experience in healthcare economics, reimbursement, health policy and government affairs.

Chip has a passion for translating national policy trends into practical go-to-market strategies and successfully achieving company reimbursement goals. He joins Endologix from Artio, where he established healthcare economics and reimbursement programs in preparation for the company’s product launches in the peripheral vascular and the end-stage kidney disease spaces.  Prior to that, Chip was instrumental in helping iCAD to navigate a new Medicare payment model for radiation oncology. Chip has held roles of increasing healthcare economics and reimbursement responsibility with PROCEPT BioRobotics, St Jude Medical, and Abbott Vascular.

Chip holds a BA in Sociology and Philosophy from Cabrini College and a Master of Public Health (MPH) from Johns Hopkins University.

Vice President, Quality

William Willis

William has over 20 years of experience within the medical device industry, having roles within Quality, Regulatory, R&D, and Operations with both start-ups and large corporations. He has extensive experience in transformational leadership, and Quality Management System and product development. Prior to joining, William was Vice President of Quality and Regulatory at Triad Life Sciences where he assisted the company with commercialization of their advanced wound management products. He has held various roles throughout his career with companies such as Becton Dickinson and Medtronic, and previously owned a medical device consulting company specializing in quality, operational management, and regulatory affairs. He has a degree in Mechanical Engineering from the University of Memphis. During his free time, he enjoys spending time with his family, fishing, and restoring classic cars.